At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of the Effects of LY545694, an iGluR5 Antagonist, in the Treatment of Subjects With Painful Diabetic Neuropathy.
In Brief
A Phase 2 clinical trial evaluating Placebo, Pregabalin, and 3 other interventions for Diabetic Neuropathy, Painful. Completed, enrolled 273 participants across 13 sites in 3 countries.
Detailed Summary
The purpose of this study is to test whether a new treatment will be safe and effective in treating pain. Patients with diabetic peripheral neuropathy will be included.
Study Details
Timeline
Interventions
LY545694 placebo BID po for 5 weeks Pregabalin placebo capsules TID po for 6 weeks
Pregabalin TID po for 6 weeks: 50 mg TID po for Week 1, 100 mg TID po for Weeks 2 - 5, and 50 mg TID po taper for Week 6 LY545694 placebo BID po for 5 weeks
LY545694 21 mg BID po for 1 week Pregabalin placebo TID po for 6 weeks
LY545694 escalated to 49 mg BID po for 1 week during Week 2. Pregabalin placebo TID po for 6 weeks.
LY545694 105 mg BID po for 5 weeks Pregabalin placebo TID po for 6 weeks